Royal Bank of Canada
NKTR icon

Royal Bank of Canada’s Nektar Therapeutics NKTR Stock Holding History

Royal Bank of Canada’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,320
Closed -$353K – 6808
2020
Q1 		$353K Buy
+1,320
New +$408K ﹤0.01% 3915
2016
Q2 		– Sell
-3,333
Closed -$688K – 6466
2016
Q1 		$688K Buy
+3,333
New +$640K ﹤0.01% 3382

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Royal Bank of Canada's NKTR Position: Q1 2026 in Review

Royal Bank of Canada increased its Nektar Therapeutics (NKTR) stake by 131% in Q1 2026, buying an estimated $522K and bringing the position to 16,181 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3509.

Royal Bank of Canada first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.6M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Royal Bank of Canada held 16,181 shares of Nektar Therapeutics worth $1.16M as of Q1 2026.
  • Royal Bank of Canada bought 9,176 Nektar Therapeutics shares in Q1 2026, an estimated $522K.
  • Nektar Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3509 holding.
  • Royal Bank of Canada first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Nektar Therapeutics position peaked at $10.6M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.